Management of Spironolactone and Lisinopril in Heart Failure

Introduction to Combination Therapy

The European Society of Cardiology recommends adding spironolactone to optimal doses of both a beta-blocker and an ACE inhibitor (or ARB) in heart failure patients, as the combination provides additive mortality and morbidity benefits 1, 2.
The combination of ACE inhibitors and spironolactone reduces mortality and prevents disease progression in heart failure, with ACE inhibitors reducing mortality and spironolactone providing additional mortality reduction when added to ACE inhibitors 1, 2, 3.

Before initiating spironolactone with lisinopril, verify serum potassium <5.0 mmol/L, serum creatinine <220 μmol/L, and eGFR >30 mL/min/1.73m² 1, 2, 4.
Monitor potassium and creatinine at 1 week and 4 weeks after initiation, then at 1, 2, 3, and 6 months after achieving maintenance dose, and subsequently every 6 months 1, 2.

Start spironolactone at 25 mg once daily when combined with ACE inhibitors, as the target dose is 25-50 mg daily, with most patients tolerating 25 mg 1, 2.

If potassium rises to 5.5-6.0 mmol/L, halve the spironolactone dose and continue lisinopril at the current dose, and recheck labs closely 1, 2, 3.
If potassium exceeds 6.0 mmol/L, stop spironolactone immediately, continue lisinopril, and monitor blood chemistry closely and treat hyperkalemia 1, 2.
If creatinine rises to >220 μmol/L, halve the spironolactone dose, and if creatinine exceeds 310 μmol/L, stop spironolactone 1, 2.

Elderly patients (≥75 years) require lower spironolactone doses and more frequent monitoring 4.
Patients with baseline renal dysfunction (eGFR 30-60 mL/min/1.73m²) require lower doses and more frequent monitoring 4.

Never combine spironolactone with both an ACE inhibitor and an ARB, as this dramatically increases hyperkalemia risk without additional benefit 1, 2.
Do not exceed 25 mg daily spironolactone in patients on ACE inhibitors with any risk factors for hyperkalemia 1, 2.